Role of Molecular Targeted Therapeutic Drugs in Treatment of Breast Cancer: A Review Article

Overview

Journal Glob Med Genet

Publisher Thieme

Date 2023 May 25

PMID 37228871

Authors

Himanshu Singh

Affiliations

Soon will be listed here.

Abstract

Breast cancer is a multifactor, multistage, and heterogeneous disease. Systemic treatment of breast cancer has changed significantly over the last decade. With a better knowledge of the pathogenesis, researchers and scientists have discovered numerous signaling pathways and synonymous therapeutic targets in breast cancer. Because of the molecular nature of breast cancer, which makes it difficult to understand, previous attempts to treat or prevent it have failed. However, recent decades have provided effective therapeutic targets for treatment. In this review, literature or information on various targeted therapy for breast cancer is discussed. English language articles were explored in numerous directory or databases like PubMed, Web of Sciences, Google Scholar, ScienceDirect, and Scopus. The important keywords used for searching databases are "Breast cancer," "Targeted therapy in breast cancer," "Therapeutic drugs in breast cancer," and "Molecular targets in breast cancer."

Citing Articles

Identification of a novel immune checkpoint-related gene signature predicts prognosis and immunotherapy in breast cancer and experiment verification.

Yin K, Guo Y, Wang J, Guo S, Zhang C, Dai Y Sci Rep. 2024; 14(1):31065.

PMID: 39730892 PMC: 11680899. DOI: 10.1038/s41598-024-82266-1.

Design and Synthesis of c-Met and HDAC Dual Inhibitors for the Treatment of Breast Cancer.

Wang Z, Shi Z, Yang S, Niu Z, Shu K, Chen L ACS Med Chem Lett. 2024; 15(9):1516-1525.

PMID: 39291032 PMC: 11403759. DOI: 10.1021/acsmedchemlett.4c00256.

The Promise and Challenges of Integrating Biological and Prevention Sciences: A Community-Engaged Model for the Next Generation of Translational Research.

Leve L, Kanamori M, Humphreys K, Jaffee S, Nusslock R, Oro V Prev Sci. 2024; 25(8):1177-1199.

PMID: 39225944 PMC: 11652675. DOI: 10.1007/s11121-024-01720-8.

Crosstalk of methylation and tamoxifen in breast cancer (Review).

Shen J, He Y, Li S, Chen H Mol Med Rep. 2024; 30(4).

PMID: 39129315 PMC: 11338244. DOI: 10.3892/mmr.2024.13304.

Combined Photosensitive Gene Therapy Effective Against Triple-Negative Breast Cancer in Mice Model.

Hu Y, Wang D, Zhang T, Lei M, Luo Y, Chen Z Int J Nanomedicine. 2024; 19:1809-1825.

PMID: 38414523 PMC: 10898360. DOI: 10.2147/IJN.S449042.

References

Sutherland S, Ashley S, Miles D, Chan S, Wardley A, Davidson N . Treatment of HER2-positive metastatic breast cancer with lapatinib and capecitabine in the lapatinib expanded access programme, including efficacy in brain metastases--the UK experience. Br J Cancer. 2010; 102(6):995-1002. PMC: 2844035. DOI: 10.1038/sj.bjc.6605586. View

J van t Veer L, Dai H, van de Vijver M, He Y, Hart A, Mao M . Gene expression profiling predicts clinical outcome of breast cancer. Nature. 2002; 415(6871):530-6. DOI: 10.1038/415530a. View

Lu H, Shu X, Cui Y, Kataoka N, Wen W, Cai Q . Association of genetic polymorphisms in the VEGF gene with breast cancer survival. Cancer Res. 2005; 65(12):5015-9. DOI: 10.1158/0008-5472.CAN-04-2786. View

Schlam I, Swain S . HER2-positive breast cancer and tyrosine kinase inhibitors: the time is now. NPJ Breast Cancer. 2021; 7(1):56. PMC: 8137941. DOI: 10.1038/s41523-021-00265-1. View

Chen Y, Alvarez E, Azzam D, Wander S, Guggisberg N, Jorda M . Combined Src and ER blockade impairs human breast cancer proliferation in vitro and in vivo. Breast Cancer Res Treat. 2010; 128(1):69-78. DOI: 10.1007/s10549-010-1024-7. View

Modi S, Stopeck A, Gordon M, Mendelson D, Solit D, Bagatell R . Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: a phase I dose-escalation study. J Clin Oncol. 2007; 25(34):5410-7. DOI: 10.1200/JCO.2007.11.7960. View

Baselga J, Im S, Iwata H, Cortes J, De Laurentiis M, Jiang Z . Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2017; 18(7):904-916. PMC: 5549667. DOI: 10.1016/S1470-2045(17)30376-5. View

Carey L, Berry D, Cirrincione C, Barry W, Pitcher B, Harris L . Molecular Heterogeneity and Response to Neoadjuvant Human Epidermal Growth Factor Receptor 2 Targeting in CALGB 40601, a Randomized Phase III Trial of Paclitaxel Plus Trastuzumab With or Without Lapatinib. J Clin Oncol. 2015; 34(6):542-9. PMC: 4980567. DOI: 10.1200/JCO.2015.62.1268. View

Chollet P, Abrial C, Tacca O, Mouret-Reynier M, Leheurteur M, Durando X . Mammalian target of rapamycin inhibitors in combination with letrozole in breast cancer. Clin Breast Cancer. 2006; 7(4):336-8. DOI: 10.3816/CBC.2006.n.047. View

10.

Miller K, Trigo J, Wheeler C, Barge A, Rowbottom J, Sledge G . A multicenter phase II trial of ZD6474, a vascular endothelial growth factor receptor-2 and epidermal growth factor receptor tyrosine kinase inhibitor, in patients with previously treated metastatic breast cancer. Clin Cancer Res. 2005; 11(9):3369-76. DOI: 10.1158/1078-0432.CCR-04-1923. View

11.

Liang Y, Besch-Williford C, Hyder S . PRIMA-1 inhibits growth of breast cancer cells by re-activating mutant p53 protein. Int J Oncol. 2009; 35(5):1015-23. DOI: 10.3892/ijo_00000416. View

12.

Scaltriti M, Chandarlapaty S, Prudkin L, Aura C, Jimenez J, Angelini P . Clinical benefit of lapatinib-based therapy in patients with human epidermal growth factor receptor 2-positive breast tumors coexpressing the truncated p95HER2 receptor. Clin Cancer Res. 2010; 16(9):2688-95. PMC: 3243489. DOI: 10.1158/1078-0432.CCR-09-3407. View

13.

Gray R, Bhattacharya S, Bowden C, Miller K, Comis R . Independent review of E2100: a phase III trial of bevacizumab plus paclitaxel versus paclitaxel in women with metastatic breast cancer. J Clin Oncol. 2009; 27(30):4966-72. PMC: 2799052. DOI: 10.1200/JCO.2008.21.6630. View

14.

Rowinsky E, Youssoufian H, Tonra J, Solomon P, Burtrum D, Ludwig D . IMC-A12, a human IgG1 monoclonal antibody to the insulin-like growth factor I receptor. Clin Cancer Res. 2007; 13(18 Pt 2):5549s-5555s. DOI: 10.1158/1078-0432.CCR-07-1109. View

15.

Zhang M, Jang H, Nussinov R . PI3K inhibitors: review and new strategies. Chem Sci. 2020; 11(23):5855-5865. PMC: 7472334. DOI: 10.1039/d0sc01676d. View

16.

Wong K, Fracasso P, Bukowski R, Lynch T, Munster P, Shapiro G . A phase I study with neratinib (HKI-272), an irreversible pan ErbB receptor tyrosine kinase inhibitor, in patients with solid tumors. Clin Cancer Res. 2009; 15(7):2552-8. DOI: 10.1158/1078-0432.CCR-08-1978. View

17.

Johnston S, Hickish T, Ellis P, Houston S, Kelland L, Dowsett M . Phase II study of the efficacy and tolerability of two dosing regimens of the farnesyl transferase inhibitor, R115777, in advanced breast cancer. J Clin Oncol. 2003; 21(13):2492-9. DOI: 10.1200/JCO.2003.10.064. View

18.

Blackwell K, Burstein H, Storniolo A, Rugo H, Sledge G, Koehler M . Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. J Clin Oncol. 2010; 28(7):1124-30. DOI: 10.1200/JCO.2008.21.4437. View

19.

Valero V, Forbes J, Pegram M, Pienkowski T, Eiermann W, von Minckwitz G . Multicenter phase III randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as first-line chemotherapy for patients with HER2-gene-amplified metastatic breast cancer (BCIRG 007 study): two highly active.... J Clin Oncol. 2010; 29(2):149-56. DOI: 10.1200/JCO.2010.28.6450. View

20.

Gong C, Zhao Y, Wang B, Hu X, Wang Z, Zhang J . Efficacy and safety of everolimus in Chinese metastatic HR positive, HER2 negative breast cancer patients: a real-world retrospective study. Oncotarget. 2017; 8(35):59810-59822. PMC: 5601780. DOI: 10.18632/oncotarget.16336. View